Comprehensive Strategies for Overcoming Barriers in Ocular Drug Delivery: Current Trends and Future Directions

Authors

Keywords:

ocular delivery, nanocarriers, ocular disease, ocular injections

Abstract

The human eye is a complex and sensitive organ, making effective drug delivery a major challenge. Its anatomical barriers, such as the precorneal, corneal, and blood-ocular barriers, significantly limit drug penetration and retention. Researchers have long focused on improving topical delivery methods to enhance drug absorption and prolong therapeutic action. Various ocular drug delivery routes have been explored, including subconjunctival, intracameral, intraocular, juxta-scleral, intravitreal, and retrobulbar. Despite these efforts, about 95.0% of available ophthalmic formulations are only available in liquid form. Other dosage forms include solids (powders, inserts, lenses), semi-solids (ointments, gels), and hybrids like in-situ gels. Nanotechnology-based carriers have recently emerged as promising tools in ocular drug delivery. These systems improve drug stability, enhance bioavailability, increase ocular permeability, and extend residence time. Additionally, they are capable of encapsulating both hydrophilic and lipophilic drugs, making them highly versatile. Various characterization methods such as in vitro, ex vivo, and in vivo studies are being used to assess the performance of these nanocarriers. This review aims to highlight the anatomical complexities of the eye, current challenges in ocular drug delivery, and the advantages and limitations of various dosage forms and routes. It also discusses recent advancements in nanotechnology-based drug delivery systems.

References

Vision Loss Expert Group of the Global Burden of Disease Study. Global estimates on the number of people blind or visually impaired by glaucoma: A meta-analysis from 2000 to 2020. Eye. 2024;38:2036-46.

Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106-16.

Graw J. Genetics of crystallins: cataract and beyond. Exp Eye Res. 2009;88:173–89.

Macwan JS, Hirani A, Pathak Y. Challenges in ocular pharmacokinetics and drug delivery. In: Nano-biomaterials for ophthalmic drug delivery. Cham: Springer International Publishing; 2016. p. 593–611.

Zignani M, Tabatabay C, Gurny R. Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels. Adv Drug Deliv Rev. 1995;16:51–60.

Akhter MH, Ahmad I, Alshahrani MY, Al-Harbi AI, Khalilullah H, Afzal O, et al. Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system. Gels. 2022;8:82. PubMed PMID: 35200463

Meyer CH, Krohne TU, Charbel Issa P, Liu Z, Holz FG. Routes for drug delivery to the eye and retina: Intravitreal injections. Dev Ophthalmol. 2016;55:63–70.

Bito LZ. The physiology and pathophysiology of intraocular fluids. Exp Eye Res. 1977;25 (Suppl):273-89.

Rajendran R, Arunachalam JP, Chidambaram S, Krishnagopal S, Krishnamurthy B, Vinayagam S, et al. Protein drug delivery using a novel maxillofacial technique targeting the visual pathway in the brain, the optic nerve, and the retina. ACS Chem Neurosci. 2023;14:3368-84.

Provis JM, Dubis AM, Maddess T. Adaptation of the central retina for high acuity vision: cones, the fovea and the avascular zone. Prog Retin Eye Res. 2013;35: 63–81.

Rutkowski P, May CA. Nutrition and vascular supply of retinal ganglion cells during human development. Front Neurol. 2016;7:49. PubMed PMID: 27092102

Manna S, Vashist P, Gupta N. National programme for control of blindness and visual impairment. CRC Press; 2023. p. 69-76.

Bakkar MM, Haddad MF, Khabour OF. The effects of tobacco waterpipe smoking on the ocular surface. Clin Exp Optom. 2022;105:500-6.

Wang L, Li X, Men X, Liu X, Luo J. Research progress on antioxidants and protein aggregation inhibitors in cataract prevention and therapy (Review). Mol Med Rep. 2025;31:22. PubMed PMID: 39513587

Toris CB. Aqueous humor dynamics and intraocular pressure elevation. In: Glaucoma editor. Elsevier; 2015. p. 47-56.

Barar J, Aghanejad A, Fathi M, Omidi Y. Advanced drug delivery and targeting technologies for the ocular diseases. BioImpacts. 2016;6:49-67.

Huang L, Zhang D, Liu M. Global trends in refractive disorders from 1990 to 2021: insights from the global burden of disease study and predictive modeling. Front Public Health. 2025;13:1449607. PubMed PMID: 40206172

Chan VF, Yong AC, Azuara-Blanco A, Gordon I, Safi S, Lingham G, et al. A systematic review of clinical practice guidelines for infectious and non-infectious conjunctivitis. Ophthalmic Epidemiol. 2022;29:473-82.

Frank RN. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol. 2002;133:693-8.

Malik D, Tarek M, Caceres del Carpio J, Ramirez C, Boyer D, Kenney MC, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014;98(Suppl_1): i11-16.

Cheema AA, Cheema HR, Cheema R. Diabetic macular edema management: a review of anti-Vascular Endothelial Growth Factor (VEGF) therapies. Cureus. 2024 Jan 21;16:e52676. PubMed PMID: 38264181

Diana P, Nicohol TM, Florencia G, Irene S. Analysis of RB1 variants in a database for correlation with pRB protein domains and clinical presentation. medRxiv [Preprint]. 2025;2025:24319096.

Ansari M, Kulkarni YA, Singh K. Advanced technologies of drug delivery to the posterior eye segment targeting angiogenesis and ocular cancer. Crit Rev Ther Drug Carrier Syst. 2024;41:85-124.

Awad R, Ghaith AA, Awad K, Mamdouh Saad M, Elmassry AA. Fungal keratitis: Diagnosis, management, and recent advances. Clin Ophthalmol. 2024;18:85-106.

Fathi-Karkan S, Amiri Ramsheh N, Arkaban H, Narooie-Noori F, Sargazi S, Mirinejad S, et al. Nanosuspensions in ophthalmology: Overcoming challenges and enhancing drug delivery for eye diseases. Int J Pharm. 2024;658:124226. PubMed PMID: 38744414.

Chandel A, Kandav G. Insights into ocular therapeutics: A comprehensive review of anatomy, barriers, diseases and nanoscale formulations for targeted drug delivery. J Drug Deliv Sci Technol. 2024;97:105785.

Batur E, Özdemir S, Durgun ME, Özsoy Y. Vesicular drug delivery systems: Promising approaches in ocular drug delivery. Pharmaceuticals (Basel). 2024;17:511. PubMed PMID: 38675470

Bisen AC, Biswas A, Dubey A, Sanap SN, Agrawal S, Yadav KS, et al. A review on polymers in ocular drug delivery systems. MedComm – Biomaterials and Applications. 2024;3:e77

Kim S, Kwon Y, Lee JY. Effect of intracameral air injection during Ahmed glaucoma valve implantation on hypertensive phase. Sci Rep. 2025;15:2738. PubMed PMID: 39838033

Khan S, Do C-W, Ho EA. Recent updates on drug delivery approaches for improved ocular delivery with an insight into nanostructured drug delivery carriers for anterior and posterior segment disorders. Drug Deliv Transl Res. 2025;15:1828-76.

Rojekar S, Parit S, Gholap AD, Manchare A, Nangare SN, Hatvate N, Sugandhi VV, Paudel KR, Ingle RG. Revolutionizing eye care: exploring the potential of microneedle drug delivery. pharmaceutics. 2024;16:1398. PubMed PMID: 39598522

Liu L-C, Chen Y-H, Lu D-W. The application of rho kinase inhibitors in the management of glaucoma. Int J Mol Sci. 2024;25:5576. PubMed PMID: 38891764

Sun Y, Zhang Y, Shen J, Shi F, Li Y, Wang C, et al. A novel Murine model for lupus-like ocular chronic graft-versus-host disease. Invest Ophthalmol Vis Sci. 2024;65:20. PubMed PMID: 38864812

Bracciano AG. Physical agent modalities. In Occupational Therapy Essentials for Clinical Competence. New York: Routledge; 2024. p. 501-19.

Smail SS. Ex vivo irritation evaluation of a novel Brimonidine nanoemulsion using the hen’s egg test on chorioallantoic membrane (HET-CAM). Cureus. 2024;16(8):e68280. PubMed PMID: 39350816

Shah SC, Smaha KM, Robin CY, Zirwas MJ, Feldman SR. A Review on the incorporation of sodium lauryl sulfate into homemade cleansers to avoid fragrances and preservatives. Journal of Integrative Dermatology. 2025.

Vincze A. Development of in vitro permeability models for optimization of drug-like compounds and dosage forms (Doctoral dissertation). Hungary: Budapest University of Technology and Economics; 2024.

Ahmed B, Jaiswal S, Naryal S, Shah RM, Alany RG, Kaur IP. In situ gelling systems for ocular drug delivery. J Control Release. 2024;371:67-84.

Losada-Barreiro S, Celik S, Sezgin-Bayindir Z, Bravo-Fernández S, Bravo-Díaz C. Carrier systems for advanced drug delivery: Improving drug solubility/bioavailability and administration routes. Pharmaceutics. 2024;16:852. PubMed PMID: 39065549

Santos G, Delgado E, Silva B, Braz BS, Gonçalves L. Topical ocular drug delivery: The impact of permeation enhancers. Pharmaceutics. 2025;17:447. PubMed PMID: 40284442

Kobal N, Marzidovšek M, Schollmayer P, Maličev E, Hawlina M, Marzidovšek ZL. Molecular and cellular mechanisms of the therapeutic effect of mesenchymal stem cells and extracellular vesicles in corneal regeneration. Int J Mol Sci. 2024;25: 11121. PubMed PMID: 39456906

Downloads

Published

2025-09-02

How to Cite

1.
N E, Revathi S, Venkateshwaran K. Comprehensive Strategies for Overcoming Barriers in Ocular Drug Delivery: Current Trends and Future Directions. BSCM [internet]. 2025 Sep. 2 [cited 2026 Jan. 26];64(4):336-43. available from: https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/278868

Issue

Section

Review Article